Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alogliptin
Drug ID BADD_D00079
Description Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Indications and Usage Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Marketing Status Prescription
ATC Code A10BH04
DrugBank ID DB06203
KEGG ID D06553
MeSH ID C520853
PubChem ID 11450633
TTD Drug ID D0NJ5H
NDC Product Code 65392-2813; 64764-625; 11532-7002; 71610-300; 66332-7003; 45802-150; 64764-250; 64764-125; 45802-103; 45802-087; 11532-7003; 50090-5574; 11532-7001; 66332-7002; 66332-7001
Synonyms alogliptin | 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile | nesina | SYR 322 | SYR322 | SYR-322
Chemical Information
Molecular Formula C18H21N5O2
CAS Registry Number 850649-61-5
SMILES CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AngioedemaCytochrome P450 3A4P08684T3784826218204
AngioedemaCytochrome P450 2D6P10635T5739226218204
HeadacheCytochrome P450 2D6P10635T5739226218204
HeadacheCytochrome P450 3A4P08684T3784826218204
HypoglycaemiaCytochrome P450 2D6P10635T5739226218204
HypoglycaemiaCytochrome P450 3A4P08684T3784826218204
NasopharyngitisCytochrome P450 2D6P10635T5739226218204
NasopharyngitisCytochrome P450 3A4P08684T3784826218204
Stevens-Johnson syndromeCytochrome P450 3A4P08684T3784826218204
Stevens-Johnson syndromeCytochrome P450 2D6P10635T5739226218204
Type IV hypersensitivity reactionCytochrome P450 3A4P08684T3784826218204
Type IV hypersensitivity reactionCytochrome P450 2D6P10635T5739226218204
Upper respiratory tract infectionCytochrome P450 2D6P10635T5739226218204
Upper respiratory tract infectionCytochrome P450 3A4P08684T3784826218204
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Acute hepatic failure09.01.03.001--Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000200%Not Available
Alanine aminotransferase increased13.03.01.0030.000300%
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.000200%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000400%
Angioedema23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.0060.000400%
Back pain15.03.04.0050.000300%
Bile duct cancer09.04.02.001; 16.07.01.0010.000157%Not Available
Blister23.03.01.001; 12.01.06.0020.000052%Not Available
Blood creatine phosphokinase increased13.04.01.0010.000200%
Blood creatinine increased13.13.01.0040.000200%
Blood glucose increased13.02.02.0020.000300%Not Available
Blood potassium increased13.11.01.0110.000300%Not Available
Blood uric acid increased13.02.04.0010.000200%Not Available
Cardiac failure02.05.01.0010.000131%
Cataract06.06.01.0010.000200%
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000052%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.000501%Not Available
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Cholecystitis09.03.01.0010.000200%
Colitis ischaemic24.04.08.012; 07.08.01.0040.000200%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.000209%Not Available
Constipation07.02.02.0010.000300%
Death08.04.01.001--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages